Related Experiment Video
Updated: Aug 11, 2026
12:59
Assessment of Oxidative Damage in the Primary Mouse Ocular Surface Cells/Stem Cells in Response to Ultraviolet-C (UV-C) Damage
Published on: February 15, 2020
Psoralens and ocular effects in humans
National Cancer Institute Monograph
|December 1, 1984
Summary
Psoralen photochemotherapy (PUVA) eye safety is achievable with proper shielding. Long-term UVA exposure risks for cataracts remain unknown, but studies show no increased rate in PUVA patients compared to general populations.
Area of Science:
- Ophthalmology
- Dermatology
- Photobiology
Background:
- Psoralen photochemotherapy (PUVA) is a common treatment for skin conditions.
- Ocular safety during PUVA therapy is a significant concern.
- Previous research has focused on acute ocular damage.
Purpose of the Study:
- To evaluate the ocular safety of psoralen photochemotherapy (PUVA).
- To establish guidelines for proper eye shielding during PUVA.
- To assess the long-term risk of cataract formation from ambient UVA exposure.
Main Methods:
- Prospective study of 68 patients undergoing PUVA therapy.
- Average follow-up duration of 4 years and 7 months.
- Comparison of cataract development rates with the Framingham Eye Study.
Main Results:
- Proper eye shielding effectively prevents acute lenticular damage during PUVA.
- No statistically significant increase in cataract development was observed in PUVA-treated patients compared to controls.
- The long-term effects of low-dose, ambient UVA exposure on cataractogenesis remain undetermined.
Conclusions:
- PUVA therapy can be considered safe for the eyes when appropriate shielding protocols are followed.
- Current evidence does not support an increased risk of cataracts in patients undergoing PUVA.
- Further research is needed to fully understand the potential risks of chronic low-level UVA exposure.
